



 **Are You an  
Investigator  
Needing Help?**

- About 
- News & Events 
- Research Resources 
- Training & Education 
- Grants & Funding 
- Community Engagement 
- Volunteer for Research 
- Tools 

<a href="#">News Center</a>	<a href="#">Newsletter </a>	<a href="#">Announcements </a>	<a href="#">Meetings </a>	<a href="#">Archives </a>	<a href="#">Contact</a>
-----------------------------	--	---	--	--	-------------------------

## Precision Health in Practice

As the first recipient of initial funding through IU's [Grand Challenges Program](#), IU School of Medicine's [Precision Health Initiative](#) aims to transform biomedical research, health care innovations and the delivery of health interventions in Indiana and beyond.

Specifically, the initiative's goals are to cure one type of cancer, cure one childhood disease and to find a way to prevent one chronic, neurodegenerative disease. Those are daunting goals, and the strategies and discoveries necessary to meet them will emerge from the Precision Health Initiative's five scientific clusters, including genomic medicine; cell and immunotherapy; a behavioral, psychological and ethics core; data and informatics science and chemical biology.

"We have set high, but not impossible, standards for ourselves with the Precision Health Initiative," said Anantha Shekhar, MD, PhD, the director of the initiative who also serves as executive associate dean for research affairs and the director of the Indiana Clinical and Translational Sciences Institute.

"As befits a grand challenge, we are also setting in place the strategies and teams of scientists we will need to reach those goals," Dr. Shekhar said.

Built on an investment of \$120 million, the resources are vast, with plans to recruit 39 new faculty members and give them access to a precision health participant cohort -- but what will this initiative do to truly transform the lives of patients? What does precision health actually look like in practice?

### Precision Health in Practice

[Bryan Schneider, MD](#), associate professor of medicine and medical and molecular genetics, used a precision medicine-based approach when treating a cancer patient last year. His patient, a 62-year-old man presented with an advanced stage of metastatic anaplastic thyroid cancer, an especially lethal and malignant form of cancer with an estimated 100% mortality rate. The average survival rate for this cancer, post-diagnosis, is three to six months.



At the time of their first meeting, the patient had already developed a large mass on his neck, evidence of an aggressive tumor that had originated in his thyroid gland, and with evidence of the cancer having spread to his lungs and rapid progression during his first line of conventional chemotherapy.

Currently, there is no optimal therapy for treating this type of cancer, and the treatments attempted on patients with this type of cancer have been unimpressive. Dr. Schneider and his team began by working to identify a genomic marker that could point to a vulnerability within the tumor. Finding a vulnerability, in this instance, was crucial. It would provide them a better chance, maybe the only chance, to effectively treat this patient. The hope of treating this cancer with only therapies used in the past? "Abysmal," said Dr. Schneider.

"From our perspective, the alternative to using the tools of precision medicine in this case after progression on standard chemotherapy was no alternative at all," Dr. Schneider said.

Through genetic sequencing of the patient, they uncovered two vulnerabilities within the tumor. The first was a mutation in a gene called BRAF. Classically, this gene mutation is seen in patients with metastatic melanoma, and there is a drug that targets this mutation with fairly good success rates. Once this was discovered, the patient was treated by his local oncologist in Fort Wayne with the drug designed to block the BRAF V600E mutation.

How did the patient respond? His neck mass was reduced in size and he showed signs of improvement. But after a few months the patient and doctors began to see growth around the tumor. The tumor had shrunk initially, but the success of the treatment was transient.

Dr. Schneider and his team turned to the second genomic marker uncovered in sequencing. They found that the patient showed an overly robust amount of PDL1 immuno-positivity, which is a marker that suggests that the tumor may be susceptible to engaging and revving up the immune system against the tumor. The PDL1 in this marker was highly positive, so they began stimulating the patient's immune system.

The response to this treatment? Complete remission. No trace of the disease visible.

The mass on his neck shrank and his CAT scan results came back completely normal. When Dr. Schneider followed up with the patient after more than a year and a half of treatment, he was still disease free. His dosage of the drug had been modified slightly due to side effects, yet tests still found no signs of disease either by scan or by physical examination.

### What does the Precision Approach Mean for the Future of Medicine?

For a patient whose disease had a lethal prognosis, and even after one positive, but ultimately transient response, his response to the second treatment and sustained success is well beyond the bounds of what doctors expected to see for a cancer like this one.

"By taking a personalized approach, we were able to treat this patient much more effectively than we would've been able to do with a more

➤ Support & Feedback

➤ Citing CTSI

➤ Newsletter

➤ Grants Login

This website is supported by [Indiana](#) and [Purdue](#) universities. Design by [IUPUI](#); concept by [Tufts CTSI](#).  
Copyright © 2014 Indiana CTSI

Contact:  
[info@indianactsi.org](mailto:info@indianactsi.org)

standard response and treatment,” said Dr. Schneider.

The Precision Health Initiative is an indication and call from the top leaders that they, and the physicians who treat and see patients, are prepared to make personalized or precision medicine a culture at IU School of Medicine and IU Health.

The IU Precision Health Initiative – which involves researchers at many IU schools and campuses, complements a national emphasis on such discovery and treatment, exemplified by President Obama’s announcement of a national Precision Medicine Initiative in February 2016.

From basic science, research that has the potential to change the face of patient care moves on the translational and clinical stage, before finally arriving at the hospital systems for bedside implementation. While this bench-to-bedside approach is standard operating procedure for medical education and health care delivery, its role in the precision health initiative is a critical factor.

What’s Next?

Precision medicine can mean a lot of things. First, it’s realizing that to an extent, doctors are already using a precision approach. When doctors meet with patients to develop treatments, they are already taking into account personal factors including the patient’s age, comorbidities and preferences. These are the flagship traits of precision medicine.

IU School of Medicine’s academic groundwork can take these precision medicine practices to the next level by using the cutting-edge genomics and epigenetics tools now available. Plus, with a statewide hospital system, doctors can take the implementation of these practices at the academic center and expand out across the state, allowing patients in northern and southern Indiana to receive the same level of care.

A [new precision genomics program](#), founded by Dr. Schneider and his colleague, [Milan Radovich, PhD](#), has since expanded to Ball Memorial Hospital at IU School of Medicine-Muncie and will soon expand to IU School of Medicine-West Lafayette Arnett Hospital and to IU School of Medicine-Bloomington.

To learn more about the process behind this initiative, and to keep up with its progress, visit [medicine.iu.edu/research](http://medicine.iu.edu/research).

INDIANA

CTSI

Clinical and Translational Sciences Institute

Accelerating Clinical and Translational Research

Login | Request Indiana CTSI account

Are You an Investigator Needing Help?

About

News & Events

Research Resources

Training & Education

Grants & Funding

Community Engagement

Volunteer for Research

Tools

News Center

Newsletter ▼

Announcements ▼

Meetings ▼

Archives ▼

Contact

2016 CTSI Annual Meeting Recap

Robert J. Lefkowitz, MD, Nobel Laureate and professor at Duke University, received the 2016 August M. Watanabe Prize in Translational Medicine and presented the keynote address as the Indiana Clinical and Translational Sciences Institute held its eighth annual meeting on Friday, Sept. 23.

The video recording of the entire meeting [is available for viewing](#). Photos from the event are available on the [IU School of Medicine Flickr page](#).

**Keynote Address: Seven Transmembrane Receptors**

In his keynote address, Dr. Lefkowitz, James B. Duke Professor of Medicine at Duke University, described more than four decades of research he and his colleagues have undertaken in the study of G Protein Coupled Receptors – also called Seven Transmembrane Receptors. Cells use the receptors to process information sent from other cells via hormones and neurotransmitters. With more than 800 such receptors, they comprise the largest class of targets for prescription drugs, and research continues to point to potential new targets for therapy. Dr. Lefkowitz and his colleague Brian Kobilka, now at Stanford, shared the 2012 Nobel Prize in Chemistry for their work with the receptors. When he began his work, Dr. Lefkowitz noted, there was no consensus that such receptors even existed.

**Ocular Neovascularization: New Mechanisms, Targets and Treatments**

Timothy W. Corson, PhD

Assistant Professor of Ophthalmology

Indiana University School of Medicine

Dr. Corson described his research into age-related macular degeneration, which is the most common cause of blindness in the elderly. The disease is characterized by choroidal neovascularization, the growth of new blood vessels that disrupt vision. Working with antiangiogenic compounds, Dr. Corson has identified a potential novel therapeutic target: ferrochelatase (FECH), a mitochondrial inner-membrane protein that previously has had no documented role in angiogenesis.

**Dissecting Cancer Signaling Pathways through Functional Genomics**

Grzegorz Nalepa, MD, PhD

Assistant Professor of Pediatrics

Indiana University School of Medicine

Dr. Nalepa described how his lab's use of functional genomics can result in unexpected and useful discoveries fueling new lines of basic science research and leading to potential new therapies, such as the discovery of an unexpected role for the Fanconi anemia signaling pathway in cell division.

**Cardiac Genetics: An Urgent Need for an Emerging Subspecialty**

Stephanie M. Ware, MD, PhD, FACMG

Professor of Pediatrics

Program Leader for Cardiovascular Genetics

Indiana University School of Medicine

Dr. Ware described the Cardiovascular Genetics program at the IU School of Medicine and the need for additional professionals in an emerging specialty field. She discussed the incidence, genetics and trends in testing associated with the areas of focus for the program: Aortopathy, cardiomyopathy, inherited arrhythmias, lipid disorders and congenital heart disease.

**Small Animal Cardiovascular Imaging in Health and Disease**

Craig J. Goergen, PhD

Assistant Professor, Weldon School of Biomedical Engineering

Purdue University

Dr. Goergen described an imaging system developed in his lab that offers significant improvements over conventional ultrasound imaging in mice. Traditional systems are limited by the fact that hearts and blood vessels are three-dimensional and dynamic systems. The solution, he said, is respiratory and cardiac gated volumetric ultrasound, which provides direct three-dimensional measurements, quantified kinematics and is useful for models of complex diseases.

**Bringing Innovation to Life: Contributions to Cardiovascular Interventions**

Sean Chambers, PhD

2016 CTSI Annual Meeting Recap \_ news.htm[1/26/2017 4:02:46 PM]

Engineering Manager

Research Interventional Radiology Development and Packaging Development

Cook Medical, Inc.

Dr. Chambers described the growth of Cook Medical from its start in Bill and Gayle Cook's Bloomington apartment to a global firm, the largest privately held device manufacturer with businesses in devices, biotechnology and cell therapy.

**Population Health in Cardiovascular Disease – Making Room for Personalized Medicine**

Rolf Kreutz, MD

Chief of Cardiology, Medical Director of Eskenazi Health Cardiac Cath Lab

Associate Professor of Clinical Medicine

Indiana University School of Medicine

Dr. Kreutz described both the benefits and limitations of evidenced-based medicine based on randomized double blind trials. The system brought dramatic improvements in cardiovascular care, but also has contributed to the ills of "cookie-cutter" medicine such as emphasizing protocol-based care and a loss of physicians' central role in delivering health care. The future of cardiovascular population health will incorporate wearables sensors and data and the integration of genomics, epigenetics and biologic disease markers.

**Panel Discussion: What is the Patient's Perspective?**

Moderated by Dr. Ware, a panel of patients and family members discussed their experiences with cardiovascular disease and the results of genetic testing.

**Poster Session:**

Following are the winners of best poster prizes for trainees and investigator categories:

**Indiana CTSI Affiliated Investigators**

- Emrin Horgusluoglu, Indiana University School of Medicine: A meta-analysis identifies ADORA2A associated with hippocampal volume in Alzheimer's disease
- Ross VerHeul, Purdue University: Controlled microfluidic assembly of therapeutic nucleic acid-loaded nanoparticles
- Meijing Wang, MD, Indiana University School of Medicine: Mesenchymal stem cell secretome improves myocardial preservation during ex-vivo cold ischemia in donor hearts

**KL2 Scholars**

- Marguerite O'Haire, PhD, Purdue University: Preliminary efficacy of service dogs as a complementary treatment for posttraumatic stress disorder in military veterans

**TL1 Post-doctoral Trainees**

- Erin Howe, PhD, University of Notre Dame: Role of Rab11b-mediated endosomal receptor recycling during brain metastatic outgrowth

**TL1 Predoctoral Trainees**

- Paula Cooper, Purdue University: The effects of autoimmune inflammation on proliferation, differentiation, and androgen receptor signaling in adult prostate stem cells
- Nick Pulliam, Indiana University-Bloomington: Novel combination therapy of DNMT inhibitor SGI-110 and PARP inhibitor BMN-673 (Talazoparib) for BRCA-proficient ovarian cancer

In addition, the top 20 posters were selected to present at the BioCrossroads Life Sciences Summit on Oct. 4. Also, representatives from Eli Lilly and Co. selected 20 posters to be presented at Lilly on Oct. 19.

[Support & Feedback](#)

[Citing CTSI](#)

[Newsletter](#)

[Grants Login](#)

This website is supported by Indiana and Purdue universities. Design by IUPUI, concept by Tufts CTSI. Copyright © 2014 Indiana CTSI

Contact:  
[info@indianactsi.org](mailto:info@indianactsi.org)



Accelerating Clinical and Translational Research



Login | Request Indiana CTSI account

Are You an Investigator Needing Help?

About

News & Events

Research Resources

Training & Education

Grants & Funding

Community Engagement

Volunteer for Research

Tools

Support & Feedback

Citing CTSI

Newsletter

Grants Login

This website is supported by Indiana and Purdue universities. Design by IUPUI; concept by Tufts CTSI. Copyright © 2014 Indiana CTSI

Contact: info@indianactsi.org

News Center

Newsletter

Announcements

Meetings

Archives

Contact

Accessing Technology Program (ATP) News - October 2016

**The IUSM Proteomics Core in Indianapolis has added new equipment to increase throughput and improve quantitation**

The IUSM Proteomics core has purchased two additional mass spectrometers to support the needs of the faculty and to have improved options for identifying post-translational modifications. This includes the Velos Pro ion trap and a Orbitrap Fusion Lumos mass spectrometer. The Velos Pro ion trap will provide core users with a robust mass spectrometer that can be used for simple protein identification projects and for new protocol development. The Orbitrap Fusion Lumos is a state-of-the-art hybrid mass spectrometer that will improve the cores capabilities in quantitative analysis of complex protein mixtures. The Fusion Lumos will also add instrument options to facilitate in-depth post-translational modification analysis and PTM site localization on specific peptides such as phosphopeptides. Both of the new instruments will complement the existing Velos Pro Orbitrap in the proteomics core to improve sample turnaround times and maximize protein identification for different sample types.

**The Center for Medical Genomics in Indianapolis will be purchasing two Illumina Sequencers**

The Center for Medical Genomics is in the process of purchasing two Illumina Sequencers, Illumina HiSeq 4000, and Illumina NextSeq 500, to increase throughput and replace older sequencers that will be retired. The dual-flow cell HiSeq 4000 System delivered the highest throughput and lowest price per sample cross multiple applications, and the NextSeq 500 System provides the flexible power and simplicity for smaller-scale transcriptome and targeted resequencing projects. The to-be-purchased equipment will significantly increase the sequencing capacity of the IUSM genomics core, and will help to ensure the fast turnaround time for both large-scale and small-scale projects.

**The Indiana Center for Biological Microscopy in Indianapolis has purchased new equipment**

Using funds obtained from the CTSI Core Equipment grant program and the Department of Medicine, the Indiana Center for Biological Microscopy has recently purchased a Fluorescence Lifetime Imaging Microscope (FLIM) system. Fluorescence lifetime is an additional dimension of fluorescence that can be used to distinguish different fluorescent molecules, to detect changes in their molecular environment (e.g., pH, hydrophobicity) or to detect fluorescence resonance energy transfer. Mounted on one of the Center's Olympus confocal/two-photon microscope systems, this system supports measurement and imaging of fluorescence lifetimes in fixed cells, living cells or living animals.

 **Are You an Investigator  
Needing Help?**

- About
- News & Events
- Research Resources
- Training & Education
- Grants & Funding
- Community Engagement
- Volunteer for Research
- Tools

[News Center](#)
[Newsletter ▼](#)
[Announcements ▼](#)
[Meetings ▼](#)
[Archives ▼](#)
[Contact](#)

## October 2016 CTSI Announcements

**Last Chance in 2016 for Population Health Short Course!**

**Population Health Short Courses-** The last Population Health Course for 2016 will be offered on **October 25<sup>th</sup>**! Registration is open now and the course is free of charge. More information here: <http://www.hiiu.edu/training>

**Registration is now open for the RCEDU Level Two Program**

The Indiana Clinical and Translational Sciences Institute (CTSI) and the IU Office of Research Compliance (ORC) are pleased to announce that registration is now open for the fall 2016 offering of the **Research Coordinator Education (RCEdu) Novice Coordinator Education--Level Two Program (formerly known as RCEP)**.

The Novice Coordinator Education program will be held on October 26 from 8:00am-4:30pm and on October 27 2016 from 8am-12:15pm in the Regenstrief Institute, 1101 W. 10<sup>th</sup> St Rooms 209 & 210.

Lectures and interactions will be presented, allowing participants to:

- Identify best practices for new research personnel related to clinical research from start to finish, including IRB submission basics, managing and reporting adverse events, and basic study budgets;
- Compare investigator responsibilities to research coordinator/associate responsibilities;
- Recognize areas that might affect research such as privacy, billing compliance, and subject recruitment and retention;
- Summarize study drug requirements and drug accountability for those interested in biomedical research; for those interested in behavioral/observational studies, summarize interviewing techniques and tools.

All interested coordinators are invited to complete the registration form found at: <https://redcap.uits.iu.edu/surveys/?s=AJTADAPXHH>. Registrants must have at least six months of experience in human subjects research. The first 50 registrants will be accepted.

There is no longer a fee for this offering. CME credit will not be provided. While this offering is not mandatory, it is highly recommended for new research personnel.

We look forward to your participation in this exciting program.

Please contact [rceducat@iupui.edu](mailto:rceducat@iupui.edu) with questions or requests for further information. General information about the RCEDU initiative can be found at [www.indianactsi.org/training/coordinators](http://www.indianactsi.org/training/coordinators).

## New Bioinformatics Seminar Offered

## STAT 598 --- Bioinformatics Seminar

**Credit: 1**

**Time:** Tuesdays 11:00am-12:00pm

**Location:** Forestry Building 216

**Instructor:** Min Zhang

### COURSE DESCRIPTION

With the recent development of modern high throughput technologies, large volumes of biomedical data have been generated and posed enormous challenges for the model development, computation, and statistical analysis on a massive scale. This weekly bioinformatics seminar features presentations of original work given by speakers from Purdue and other institutions.

The objective of this seminar is to provide a forum for researchers with different expertise in biology related areas, computation, and statistics. It is intended to promote interdisciplinary training as well as potential collaborations across multiple disciplines on campus.

Please contact Min Zhang ([minzhang@purdue.edu](mailto:minzhang@purdue.edu)) for speaker and topic suggestions.

## 2b2: Medical Records Access and Funding Opportunities


**Try the New and Improved Indiana CTSI i2b2**

Over the past few months, the i2b2 technical team at Regenstrief Institute Center for Biomedical Informatics has been working diligently to improve the functionality of i2b2 and the completeness of the data. [READ MORE](#)

This website is supported by Indiana and Purdue universities. Design by IUPUI; concept by Tufts CTSI. Copyright © 2014 Indiana CTSI




Contact:  
[info@indianactsi.org](mailto:info@indianactsi.org)

---



INDIANA CTSI  
Clinical and Translational Sciences Institute

Accelerating Clinical and Translational Research



Login | Request Indiana CTSI account

Are You an Investigator Needing Help?

About

News & Events

Research Resources

Training & Education

Grants & Funding

All CTSI Funding

All Open RFPs

Other Funding

Grant Management

Citation Information

No Cost Extensions

Community Engagement

Volunteer for Research

Tools

## All Open Indiana CTSI Request for Proposals

This page lists all Indiana CTSI funded proposals currently accepting applications. You can click on the grant title for further details for that grant. The "START" link at the bottom of each grant will take you to the CTSI grants system (which requires login) and start the application process.

### Infectious Diseases T32 Training Program- 2017.03

#### APPLICATION SUBMISSION DEADLINE - MARCH 07, 2017

This training opportunity is a collaborative effort between the Division of Infectious Diseases (ID), Department of Medicine; the Sections of Adolescent Medicine and Infectious Disease & Global Health, Department of Pediatrics; the Department of Dermatology and; the Department of Microbiology and Immunology.

The primary mission of this multidisciplinary training program is to train well qualified MD and PhD scientists for productive and sustainable careers in research. The scope of training ranges from bench science to implementation research. In addition, as team science is rapidly becoming the primary mode of operation for biomedical scientists addressing complex questions related to human health, this opportunity emphasizes training investigators who are familiar with the practices, procedures, and languages of collaboration necessary for creating and working within a productive team. This opportunity uses a broad based integrative approach, supported by excellent mentors, in order to achieve the goal of training superb researchers for the next generation.

### IIMR VA Young Investigator Award (YIA) - 2017.02

#### LETTER OF INTENT (LOI) DEADLINE JANUARY 18, 2017

#### APPLICATION SUBMISSION DEADLINE - FEBRUARY 08, 2017

IIMR's mission is to promote and enhance research efforts that will ultimately result in improved quality of life for veterans and for the greater population. In support of that mission, IIMR works to encourage investigators to develop their research careers by working with IIMR and the VA and veterans to answer important questions. One way IIMR encourages investigators is to sponsor the annual Young Investigator Award Program, which provides a competitive experience for investigators to explore the possibilities of VA-related research.

The IIMR is currently seeking submissions for clinical, basic science and translational research. It is expected that two meritorious awards will be funded through this RFA cycle. Project budgets should be limited to those funds necessary to carry out the research project and should be limited to \$25,000.

Please note: If you want to attend a grants writing workshop or educational session prior to completing your YIA submission, please contact the IIMR via Mary.Gray1@va.gov, 317.988.9544, or refer to the IIMR website at iimrindy.org. Our office will be happy to assist you in enrolling in a workshop or session.

### MD/MS Fellowship Program: Year in Translational Research for Medical Students - 2017.03

#### SUBMISSION DEADLINE - MARCH 07, 2017 (4:00 PM)

The Indiana Clinical and Translational Research Institute (CTSI) is seeking applicants for a special research fellowship in translational research. This fellowship program will be awarded through a competitive process. CTSI will provide an annual stipend and one year of health insurance coverage for as many as two IUSM medical students interested in taking a year out of medical school to pursue an M.S. in Translational Science.

### CTSI - IU Kelley MBA Core and Project Business Management Assistance - 2017.01

#### SUBMISSION DEADLINE – JANUARY 16, 2017 (5:00 PM)

The Indiana CTSI, jointly with the IU Kelley School of Business, offers to provide for a team of 2-5 Indiana Kelley MBA students (from the residential-MBA program in Bloomington) to be your partners for the project as a part of their independent study program for course credit. Project duration will be 8 weeks. Selected cores will be expected to engage with the MBA students for initial project scope (2 hours), additional follow-up or onsite meetings (8-12 hours) and a final project close-out (1-2 hours). The MBA students will contribute 30-100 hours each (depending on the project scope, number of team members and course credit assignment) to the project progression in turn. **Selected projects will commence in February - March 2017 and will be completed by early May.**

### CTSI Young Investigator Award in Clinical - Translational Research - 2017.01

#### SUBMISSION DEADLINE - JANUARY 17, 2017 (5:00 PM).

The Indiana Clinical and Translational Sciences Institute (CTSI) is seeking applicants for the CTSI Young Investigator Awards in Clinical-Translational Research. These awards are designed to provide promising junior investigator faculty with the opportunity to be mentored in research-intensive multi-disciplinary settings toward the goal of developing careers in clinical-translational research. Clinical research includes epidemiological studies, clinical trials, or other investigations involving human subjects. Translational research consists of either "T1 research"



(interface of basic science to human studies) or "T2 research" (interface of human studies to the community). To be eligible, candidates must fall into 1 of the following 2 categories: 1) Clinician-scientists with a doctoral degree (physicians, nurses, dentists, pharmacists, clinical psychologists, optometrists, veterinarians, allied health care professionals, etc.) or 2) Basic scientists with a PhD who are doing translational research, which involves some component of human subjects research and has high potential for early translation in impacting patient care.

**CTSI Postdoctoral Training Awards in Translational Research - 2017.01**

**SUBMISSION DEADLINE - January 13, 2017 (5:00 PM).** The Indiana Clinical and Translational Sciences Institute (CTSI) is seeking applicants for special postdoctoral training awards in translational research. In biomedical terminology, translational research refers to what is popularly termed as "bench to bedside"; the process by which research in the lab translates into patient treatment. Translation may involve applying discoveries made during research (in the lab, through animal studies, etc.) to the development of clinical trials and studies in humans, or carrying out research aimed at enhancing the adoption of best practices, or both. To be eligible, candidates must have received a PhD or equivalent degree from an accredited domestic or foreign institution. Please refer to the competition guidelines for full eligibility criteria.

**Ralph W. and Grace M. Showalter Research Trust - 2017.01**

**KC ROUTING DEADLINE - January 10, 2017 (5:00 PM).**

Since 1975, IUSM has received research funding through gifts made possible from the Ralph W. and Grace M. Showalter Research Trust Fund. The areas of appropriate biomedical research, eligible for funding, are broad and described by the benefactors as "the type of medical research that is most likely to permanently benefit mankind." Donor intent prohibits the use of Showalter Trust funds for research in psychiatry, sociology, or social studies. Applications for funding from the Ralph W. and Grace M. Showalter Research Trust will be reviewed in two stages. An initial review by the IUSM Biomedical Research Committee (BRC) will select the most meritorious proposals for further discussion and ranking. The BRC will then provide a recommended ranking to the Showalter Trustees who conduct a second review. Final funding decisions are made by the Showalter Trustees. Applications for funding beginning July 1, 2017 must be routed to the Office of Research Administration (ORA) by 5pm on Tuesday, January 10. ORA approved applications should then be uploaded to the CTSI website no later than 5:00 pm Tuesday, January 17. Only current full-time faculty (non-visiting status) having a primary appointment in IUSM and a rank of assistant professor or assistant scientist are eligible to apply for funding from the Showalter Research Trust. Note that the same proposal may not be submitted as both a Biomedical Research Grant and a Showalter Trust application. If eligible for both programs, the investigator is encouraged to submit to the Showalter Trust.

**Biomedical Research Grant - 2017.01**

**SUBMISSION DEADLINE - January 10, 2017 (5:00 PM).**

The Biomedical Research Grant program is open to all IU School of Medicine (IUSM) faculty that are full-time, regardless of tenure status, having an appointment of Assistant/Associate/Full Professor and Assistant/Associate/Full Scientist. In general, two categories of research projects will benefit from this program: 1) research projects of investigators new to IUSM who do not yet have extramural funding and who need support to acquire the preliminary data necessary to compete for extramural funding; 2) research projects of established IUSM investigators who are between funding periods from extramural sources.

**Design and Biostatistics Program (DBP) Pilot Grant - 2017.02**

**LETTER OF INTENT (LOI) DEADLINE - DECEMBER 16, 2016**

**FULL APPLICATION DEADLINE - FEBRUARY 6, 2017 (5:00 PM)**

The Design and Biostatistics Program (DBP) of the Indiana Clinical and Translational Science Institute (CTSI) is comprised of 8 units with associated expertise: 1) Department of Biostatistics, IU School of Medicine and Fairbanks School of Public Health; 2) Division of Hereditary Genomics, Department of Medical & Molecular Genetics, IU School of Medicine; 3) Computational Biology, Center for Computational Biology & Bioinformatics, IU School of Medicine; 4) Department of Epidemiology, Fairbanks School of Public Health; 5) Department of Statistics, Purdue College of Science; 6) Department of Applied & Computational Math & Statistics, Notre Dame School of Science; 7) Department of Statistics, IU Bloomington College of Arts & Sciences; 8) Department of Epidemiology and Biostatistics, IU Bloomington School of Public Health.

To achieve its objectives and stimulate development for emerging translational research needs, the DBP will fund innovative pilot projects that support methodological research of faculty members in the eight units that comprise the DBP. The total budget for the entire RFA is \$20,000, and it is expected that up to two awards will be funded at approximately \$10,000 per award for a twelve month duration. The objective of this mechanism is to fund research proposals that will synergize methodological strengths and translational biomedical research of the DBP, and in particular, the following types of research proposals:

- Research projects that propose to develop novel methodology (such as biostatistical, epidemiological, genetic, and bioinformatics methods).
- Research projects that match novel methodology with translational science needs.
- Research projects that have high potential to obtain external funding.

Preference will be given to investigators who have not already received extramural funding. Applications to this program are expected to be **\$10,000 per award** and are of **one (1) year duration**.

**START**

**CTSI Pre-Doctoral Training in Translational Research - 2016.12**

**CV SUBMISSION PRIOR TO APPLICATION ( via ictsi@purdue.edu) DEADLINE - DECEMBER 5, 2016**

**FULL APPLICATION DEADLINE - DECEMBER 12, 2016 (4:00 PM)**

The Indiana Clinical and Translational Sciences Institute (CTSI) is seeking applicants for special predoctoral training awards in translational research. In biomedical terminology translational research refers to what is popularly termed "bench to bedside", the process by which research in the lab "translates" into patient treatment. Translation may involve applying discoveries made during research (in the lab, through animal studies, etc.) to the development of clinical trials and studies in humans, or carrying out research aimed at enhancing the adoption of

best practices, or both. These two types of translational research are usually described as consisting of either "T1 research" (basic biomedical research, e.g. study disease at a molecular or cellular level, as it progresses to the development of new treatment options at the clinical level) or "T2 research" (enhancing access to and the adoption of evidence-based strategies in clinical and community practice, institutionalizing programs, products, and services to improve health). These awards are aimed at predoctoral students whose research is at any point along this spectrum. **Funding is for two years (with the 2nd year of funding contingent upon satisfactory progress).** Benefits include a stipend as well as health insurance and partial coverage of tuition and fees.

**Center for Diabetes and Metabolic Diseases' Pilot and Feasibility - 2017.03**

**LETTER OF INTENT (LOI) DEADLINE - JANUARY 9, 2017 (5:00 PM)**

**FULL APPLICATION DEADLINE - MARCH 6, 2017 (5:00 PM)**

This funding opportunity announcement invites applications from investigators at Indiana University (IUSM, IUB, etc.), IUPUI, and Purdue. The program will be particularly directed at new investigators and established investigators new to diabetes-related research. The program will also consider established diabetes investigators pursuing high impact/high risk projects or projects that are a significant departure from their usual work. The campuses are ideal for establishing interdisciplinary collaborations and forging new partnerships between basic scientists and clinical researchers, and such collaborations are encouraged. Work supported by these funds is expected to lead to submissions of major extramural grants (R01/equivalent NIH, major foundation awards, DOD, etc.).

**START**

**Global Health Research Pilot Projects -2016.12**

**SUBMISSION DEADLINE – DECEMBER 12, 2016 (5:00 PM)**

The Indiana CTSI with the IU Center for Global Health is soliciting proposals from applicants developing or currently involved in collaborative global health research projects. The purpose of this RFA is to foster and encourage the development of new collaborative interdisciplinary research that seeks to identify innovations to address key global health challenges and improve health outcomes in resource limited settings. This RFA will fund pilot research projects with: (1) a high potential for attracting new extramural research funding; (2) a focus on strengthening collaborative multidisciplinary research collaborations between Indiana CTSI partner institutions (IU, Purdue, and Notre Dame) and key academic research centers abroad; and (3) an emphasis in key, high-yield, research-related initiatives, including basic and translational sciences research, biobanking, cancer, population focused disease control, informatics and decision support systems, and implementation research dissemination.

**Post-Doc Challenge - Funding to Utilize CTSI-Designated Cores - 2017.02**

**FULL APPLICATION DEADLINE - TUESDAY, FEBRUARY 28, 2017 (5:00 PM)**

The Indiana Clinical and Translational Sciences Institute (CTSI) is soliciting proposals from postdoctoral researchers to develop translational research through the use of technologies and expertise available at the Indiana CTSI-designated core facilities available at all partner institutions. Translational research refers research in the lab that eventually translates into patient treatment to improve human healthcare. Translation involves applying discoveries made during research (in the lab, through animal studies, etc.) to the development of clinical trials and studies in humans.

CTSI-designated core facilities are cores that undergo a yearly accreditation process through the Indiana CTSI for all partner institutions. The Postdoc Challenge offers postdoctoral researchers at Indiana University, Indiana University School of Medicine, IUPUI, Purdue University, and the University of Notre Dame valuable proposal writing and reviewing experience in areas related to translational research through the use of one or more of the CTSI-designated core facilities at any of the partner universities. This is a competitive opportunity for a \$5,000 award in the form of an expense account for use of core facility services. Funding is to be used only for services provided by the core facilities. Indiana CTSI-designated core facilities are listed on the CTSI HUB. (<https://www.indianactsi.org/servicecores>)

Applications to this program are **limited to \$5,000** and are of **one (1) year duration**.

**START**

**Adult Gastrointestinal and Liver Diseases Research Pilot Grant - 2016.11**

**LETTER OF INTENT (LOI) DEADLINE - FRIDAY, OCTOBER 21, 2016**

**FULL APPLICATION DEADLINE - MONDAY, NOVEMBER 7, 2016 (5:00 PM)**

The Indiana Clinical and Translational Sciences Institute (CTSI), in conjunction with the Division of Gastroenterology/Hepatology in the Department of Medicine, is soliciting proposals for pilot projects from investigators to develop and promote translational and transdisciplinary collaborative research projects in adult gastrointestinal and liver diseases. The objective is to fund studies that (a) establish or strengthen already established collaborations between faculty members in the GI Division and investigators from other departments and schools at IUSM, IUPUI and Purdue University; (b) generate preliminary data for extramural funding applications investigating adult GI and liver disorders.

The areas of interest include (a) acute and chronic liver diseases; (b) GI and hepatobiliary malignancy; (c) inflammatory bowel disease; (d) GI motility disorders; (e) chronic abdominal pain; and (f) chronic functional bowel disorders. The proposal should demonstrate tangible evidence that the collaboration will lead to a multiyear federal grant application.

Applications to this program are **limited to \$35,000** and are of **one (1) year duration**. Up to two grants will be awarded per grant cycle.

**Indiana Spinal Cord & Traumatic Brain Injury Research Fund - 2016.12**

**FULL APPLICATION DEADLINE - FRIDAY, DECEMBER 9, 2016 (5:00 PM)**

The overall objective of the Indiana Spinal Cord & Traumatic Brain Injury Research Fund program is to foster and encourage research for the prevention, treatment and cure of spinal cord and traumatic brain injuries, including acute management, medical complications, rehabilitative techniques, and neuronal recovery. Collaborations are encouraged between Indiana-based researchers as well as with researchers located outside the state of Indiana, including researchers in other countries. Even though the Indiana statute encourages collaborations with

researchers outside of Indiana, the primary research should be Indiana-based. Collaborations can be between Principal Investigators (PIs) at the same institution, different institutions, or a PI and a company. Salary support for collaborators outside of Indiana will be limited.

Applications to this program are **limited to \$160,000** and are of a **two (2) year duration**, with a \$80,000 per year maximum.

**Pilot Funding For Research Use of Core Facilities - 2016.10**

**FULL APPLICATION DEADLINE - FRIDAY, OCTOBER 7, 2016 (5:00 PM)**

The Indiana CTSI Pilot Funding program is intended to promote the use of technologies and expertise afforded by the Indiana CTSI Core Facilities available at all partner institutions. Successful proposals will demonstrate outstanding scientific merit that can be linked to generating extramural funding or novel intellectual property (IP). Success of the program will be viewed, in part, by the fostering of new funded grants or providing significant contributions to grant renewals. Therefore, proposals will be judged with equal measure on scientific merit and the likelihood of generating new IP or extramural grant support.

**Indiana University Health Values Fund: Pilot and Feasibility Education Program - 2016.11**

**FULL APPLICATION DEADLINE - NOVEMBER 4, 2016 (5:00 PM)**

Indiana University Health's strength in providing excellent patient care is partially based on involvement in the continuous development of new, pre-eminent health care professionals throughout the entire workforce and innovative care delivery models. The Indiana University Health is seeking applicants for the IUH Pilot and Feasibility Education Program. The specific areas of opportunity of the program include the following: 1) Educational efforts in the field of ethics involving students, residents, or staffs; 2) Support for translation or dispersal of knowledge (e.g. library); 3) Education in Health Evaluation and Services, including outcomes evaluation and procedures; 4) Educational efforts especially with residents and staff which address ethical, socioeconomic, medical, legal and cost containment, or other issues affecting medical practice, quality of life, and access to health care; 5) Educational efforts in an ambulatory setting and/or promotion of continuity of care across care settings; 6) Education involving alternate approaches to health care including spirituality, end of life care, etc., or educational efforts which attempt to integrate complementary and traditional medicine in support of providing holistic care; 7) Educational efforts involving delivery of chronic care; 8) Primary care education devoted to holistic care; 9) Education in research principles; 10) Education in the development of and delivery of health promotion projects; 11) Educational efforts in faculty, resident, professional and/or staff development as related to teacher/learner issues; and 12) Education in quality improvement.

Applications to this program are **limited to \$100,000** and are of a **two (2) year duration**, with a \$50,000 per year maximum.

**Indiana University Health Values Fund: Pilot and Feasibility Research Program - 2016.11**

**LETTER OF INTENT (LOI) DEADLINE - OCTOBER 21, 2016**

**FULL APPLICATION DEADLINE - NOVEMBER 4, 2016 (5:00 PM)**

Indiana University Health is seeking applicants for the IUH Pilot and Feasibility Research Program. The priority areas of the program include the following areas: 1. Discovery of new knowledge and the development of new diagnostic treatment and prevention modalities to improve patient care outcomes; 2. Promotion of health in the population and the provision of health care of the highest quality to its patients while assisting the hospital to become more efficient; 3. Projects that demonstrates collaboration between the Indiana University Health hospital campuses.

Applications to this program are **limited to \$100,000** and are of a **two (2) year duration**, with a \$50,000 per year maximum.

**Indiana University Health Values Fund: Grand Challenge Grant - 2016.11**

**LETTER OF INTENT (LOI) DEADLINE - OCTOBER 21, 2016**

**FULL APPLICATION DEADLINE - NOVEMBER 4, 2016 (5:00 PM)**

This is a relatively new component of the IU Health Values Fund Grant Program. Values Fund expenditures represent an expression of Indiana University Health's seven Core Values. The Grand Challenge is funded in support of the Indiana University Health values. The proposed "Grand Challenge" Values grants will compliment Indiana University Health's strength in providing excellent patient care and health education by adding a new dimension this award round by addressing '*smoking cessation studies as well as projects focusing on behavioral health*'. This new focus further aligns IU Health with the State of Indiana's strategies to combat smoking and behavioral health. Thus, the IU Health Grand Challenge (IUH GC) applications are expected to make a significant impact on key communities served by IU Health and demonstrate how the awards will improve the health outcomes of targeted communities in Indiana and beyond. Grand Challenge proposals will be accepted that focus specifically on population health research on any of the following two topics: 1) Reduce tobacco use and/or exposure to secondhand smoke that scales across the health system, strengthens community partnerships, and advances public health impact of IUH/IUSM; 2) Develop a model of care and necessary workforce to address serious behavioral health problems that can be deployed across the health system and advances IUH/IUSM's public health impact and community partnerships.

Applications to this program are **limited to \$500,000** and are of **two (2) year duration**, with a \$250,000 per year maximum.

**Indiana University Health Values Fund: Integration of Spiritual and Religious Dimensions in Health Care - 2016.11**

**LETTER OF INTENT (LOI) DEADLINE - OCTOBER 14, 2016 (5:00 PM)**

**FULL APPLICATION DEADLINE - NOVEMBER 4, 2016 (5:00 PM)**

IU Health's strength in providing excellent patient care is rooted in the religious and spiritual heritage of its institutions. The spiritual calling to heal the sick brings vitality and meaning to patient care within the IU Health community. The Joint Commission on Accreditation has emphasized spiritual care as a vital part of the mission of health care institutions. IU Health will succeed in meeting its mission to provide holistic care to our patients with new programs to integrate spiritual care into patients' treatment plans and to develop methods and find solutions to address all the needs of those we serve. The Values Fund offers a unique resource that will allow us fulfill our mission and uphold our values.

Indiana University Health is seeking applicants for the Indiana University Health Values Fund for the Integration of Spiritual and Religious

Dimensions in Health Care. The specific areas of opportunity of the program include the following: 1) Projects that seek to foster a "whole person perspective" in health care; 2) Projects that foster policies and procedures that enhance respect for patient rights and responsibilities; 3) Projects that coordinate and provide a forum and consultation in the area of religious and moral meaning in bioethics; 4) Projects that research the role of religion, spirituality, and/or ethics in health and healing; 5) Projects that provide a service as a religious and ethical values resource center within the IU Health network and the broader community; 6) Projects that support innovation in spiritually integrated counseling, particularly for low income persons and families; and 7) Projects that provide a linkage with, and liaison between, the religious community and IU Health, addressing the continuum of care and wellness issues in our society.

Applications to this program are **limited to \$100,000** and are of a **two (2) year duration**, with a \$50,000 per year maximum.

**IU School of Medicine/Purdue University - Devices Advancing Surgical Care - 2016.10**

**SUBMISSION DEADLINE - OCTOBER 31, 2016 (5:00 PM).**

The Indiana Clinical and Translational Sciences Institute (CTSI) is please to request applications for funding to develop potential devices in the broad area of surgery. The successful application will involve investigators from the Department of Surgery at Indiana University School of Medicine and faculty from Purdue University. Awards will be competitive and may not exceed \$100,000 for up to two (2) period. Investigators from both institutions are encouraged to come up with innovative ideas that can result in a device that improves human health. For questions regarding scope, review of the proposal, or financial issues related to budgeting and grant submission contact Lane Coffee at [rlcoffee@iu.edu](mailto:rlcoffee@iu.edu) or via phone at 317-278-2150.

**Dr. Charles Fisch Cardiovascular Research Award**

**PROPOSAL SUBMISSION DEADLINE - 1) FIRST REGULAR BUSINESS DAY IN APRIL and 2) FIRST REGULAR BUSINESS DAY IN SEPTEMBER (5:00 PM).**

Indiana University School of Medicine announces the availability of Dr. Charles Fisch Cardiovascular Research Award to support cardiovascular research for young investigators or more senior investigators, embarking on a new research direction.

Applicants may request up to \$60,000 total, although particularly meritorious proposals that have well-justified budget needs as high as \$100,000 may be considered. Successful proposals will demonstrate scientific merit and a potential for generating extramural funding. In addition, prioritization will be given to those projects that utilize more than one IU Health hospital or facility for leveraging existing patient populations or clinical programs and/or projects that will potentially lead to improvements in the quality of care for IU Health patients. Applicants must have an Indiana University faculty appointment in the Department of Cardiology, Department of Medicine to apply for research program support. Clinical fellows and postdoctoral researchers in the Division of Cardiology may apply for research fellowship support under a faculty member in the Division of Cardiology.

**START**

**Eli Lilly-Stark Neurosciences Pre-Doctoral Research Fellowship in Neurodegeneration - 2016.08**

**LETTER OF INTENT (LOI) DEADLINE - AUGUST 5, 2016**

**FULL APPLICATION DEADLINE - AUGUST 26, 2016 (5:00 PM)**

The Stark Neurosciences Research Institute and the Indiana Clinical and Translational Sciences Institute (CTSI) are seeking applicants for special pre-doctoral training fellowships in translational neurodegenerative disease research. We seek applicants whose research is focused on age-related neurodegeneration, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, chronic traumatic encephalopathy, among others. Translational research refers to what is popularly termed as "bench to bedside"; the process by which research in the lab translates into patient treatment. Translational research fosters the multidirectional integration of basic research, patient-oriented research, and population-based research, with the long-term aim of improving the health of the public. Translation can involve everything from basic science discoveries in the lab that directly focus on human disease states, through animal studies and drug development to the development of clinical trials and studies in humans.

Annual stipend (plus applicable health insurance) is aligned with current NIH recommendations. Annual supplement of \$7,500 to be used for travel, computers, and general supplies. Initial funding duration is for one (1) year, and is renewable for one (1) additional year pending review and demonstration of satisfactory progress.

**Eli Lilly-Stark Neurosciences Post-Doctoral Research Fellowship in Neurodegeneration - 2016.08**

**LETTER OF INTENT (LOI) DEADLINE - AUGUST 5, 2016**

**FULL APPLICATION DEADLINE - AUGUST 26, 2016 (5:00 PM)**

The Stark Neurosciences Research Institute and the Indiana Clinical and Translational Sciences Institute (CTSI) are seeking applicants for special post-doctoral training fellowships in translational neurodegenerative disease research. We seek applicants whose research is focused on age-related neurodegeneration, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, chronic traumatic encephalopathy, among others. Translational research refers to what is popularly termed as "bench to bedside"; the process by which research in the lab translates into patient treatment. Translational research fosters the multidirectional integration of basic research, patient-oriented research, and population-based research, with the long-term aim of improving the health of the public. Translation can involve everything from basic science discoveries in the lab that directly focus on human disease states, through animal studies and drug development to the development of clinical trials and studies in humans.

Annual stipend (plus applicable health insurance) is aligned with current NIH recommendations. Annual supplement of \$7,500 to be used for travel, computers, and general supplies. Initial funding duration is for one (1) year, and is renewable for one (1) additional year pending review and demonstration of satisfactory progress.

**Activity-Based Therapy Grant Program - Indiana Spinal Cord & Traumatic Brain Injury Research Fund - 2016.09**

**LETTER OF INTENT (LOI) DEADLINE - AUGUST 12, 2016**

**FULL APPLICATION DEADLINE - SEPTEMBER 9, 2016 (5:00 PM)**

The State of Indiana established the research fund known as the Indiana Spinal Cord and Traumatic Brain Injury Research Fund (ISCBIRF) effective July 1, 2007. This fund, established under Indiana Code (IC) 16-41-42-4, will consist of appropriations, gifts and bequests, fees deposited in the fund under IC 9-29-5-2, and grants received from the federal government and private sources.

Effective July 1, 2015 this fund was supplemented and additionally authorized by legislation to provide prescribed, defined, and limited support to non-profit organizations corresponding to 501(c) 3 Federal tax status engaged in rehabilitative clinical care employing "activity based" approaches.

The overall objective of this program is to foster and encourage activity-based therapy programs for the prevention, treatment, and cure of spinal cord and traumatic brain injuries, including acute management, medical complications, rehabilitative techniques, and neuronal recovery.

Applications to this program are limited to \$1,000,000 (maximum of \$600,000 during the first year; \$400,000 during the second year) for up to two (2) years in duration based on appropriate achievement of milestones and progress reports.

**IU Grant Linking University-wide Expertise (GLUE) Awards - 2016.09**

**LETTER OF INTENT (LOI) DEADLINE - AUGUST 5, 2016**

**FULL SUBMISSION DEADLINE - SEPTEMBER 2, 2016 (5:00 PM)**

Indiana University, Bloomington, Provost's Office and the Indiana Clinical and Translational Sciences Institute (CTSI) are seeking applicants for the IU Grant Linking University-wide Expertise (GLUE) Award. The objective of the GLUE award is to support "planning and team building across campuses to develop large multi-investigator and/or multi-project, milestone-driven, translational research teams who are planning to submit multi-year, extramural grant applications with annual budgets of \$500K or more in direct costs." It is expected that these planning/seed grants will increase multidisciplinary collaborations, institutional competitiveness, opportunities for extramurally funded training grants and overall institutional funding. The GLUE funding is available to collaborative teams in which the lead PI of the research team is from IUB, and the other members of the team are typically from IU campuses such as IUPUI and IUSM (or in deserving cases, any other CTSI university partner campus).

Applications to this program are limited to \$100,000 per year for up to two (2) years in duration based on appropriate achievement of milestones and eventual submission of an extramural grant application.

**Technology Enhancement Awards - 2016.07**

**SUBMISSION DEADLINE - FRIDAY, JULY 08, 2016 (5:00 PM).**

A common critical gap in commercialization of technologies originating from the academic labs is the funding necessary to develop a robust commercialization relevant data package to reduce the risk of investment in early stage technologies. The Indiana CTSI and Indiana University School of Medicine through the office of the Associate Dean for Entrepreneurship and its Industry Collaboration Portal (ICP), are partnering with the newly created Indiana Center for Biomedical Innovation (ICBI) at IU Health to help fill this critical gap through a new support program, Technology Enhancement Awards (TEA), for early stage technologies. The technology may already reside in a start-up company or a clear plan exists to place it into a start-up. The New Program will partner with the highly successful SPARK program at Stanford University.

**Indiana Drug Discovery Alliance - 2016.07**

**SUBMISSION DEADLINE - FRIDAY, JULY 01, 2016 (5:00 PM).**

The Molecular Therapeutics Program, a part of the Indiana Clinical and Translational Sciences Institute, seeks applications for a competitive program that will provide funds and essential consultation to support the early stage development of therapeutics. This opportunity is provided in concert with the Indiana Drug Discovery Alliance (IDDA), an advisory panel and clearinghouse for drug discovery and development resources at the Indiana-CTSI member institutions of Indiana University, Purdue University and the University of Notre Dame.

**Call for Proposals:** The Molecular Therapeutics Program will support the new collaborations and/or the use of core facilities that enable the translation of fundamental research related to drug discovery. Critical project feedback will be provided from a team of experienced industry and academic experts on the group's internal advisory committee, as well as through ad-hoc, project-specific pharmaceutical expert reviewers.

**A detailed budget is not required at this time. Support projects will develop a budget of up to \$15,000 in consultation with the IDDA.**

**Strategic Pharma-Academic Research Consortium Awards Program - 2016.05**

**LETTER OF INTENT SUBMISSION DEADLINE - FRIDAY, MARCH 18, 2016**

**FULL PROPOSAL SUBMISSION DEADLINE - FRIDAY, JUNE 17, 2016**

The Midwest Strategic Pharma-Academic Research Consortium (SPARC) has been established by the Indiana Clinical and Translational Sciences Institute. The members of the consortium consist of both academic and pharmaceutical companies. The inaugural CTSA members and pharmaceutical Companies are: Indiana University, Ohio State University, Northwestern University, Washington University in St. Louis, The University of Chicago, Eli Lilly and Co. and Takeda Pharmaceuticals Inc. SPARC is seeking applicants for the Midwest Strategic Pharma-Academic Research Consortium Awards Program. The consortium expects to support projects related to human autoimmune disease with the following criteria: (1) research is in the non-competitive space of mutual interest that address scientific and technological research challenges confronting the pharmaceutical industry; (2) project is to be executed with the network of Academic Members; (3) study is designed to further the understanding of disease biology, potentially leading to the identification of novel therapeutic targets; (4) to promote an improved definition of autoimmune disease according to molecular taxonomy rather than as clinical syndromes; and/or (5) to improve the prediction of response to therapy and the early detection of response / non-response in autoimmune diseases where this is not apparent at a clinical level. Successful proposals will demonstrate the following: A) Have at least **two (2)** Project Specific Personnel from different Academic Member institutions for which such institutions agree to contribute the requisite cost share funding for the research proposal. B) Address the non-competitive space of mutual interest to the Members and scientific and technological research challenges confronting translational research. C) Include the Research Plan and related budget for the study proposal. Applications to this program are limited to \$400,000 and are 24 months (2 years) in duration.



CHEP Community Based Research Awards - 2016.06

**SUBMISSION DEADLINE - JUNE 1, 2016. (5:00 PM).** The Indiana CTSI CHEP is soliciting proposals from applicants developing or currently involved in collaborative, community-based research projects. Namely, this RFA will fund pilot projects generated from community-university partnerships. The pilot project can serve a variety of purposes such as program evaluation, feasibility or preliminary data for extramural grant submissions, etc. Potential applicants are encouraged to identify, or further develop, collaborative relationships to be strengthened through this grant opportunity.

Adult Gastrointestinal and Liver Diseases Research Pilot Grant Program 2016.05

**LETTER OF INTENT (LOI) DEADLINE - APRIL 15, 2016.**  
**FULL SUBMISSION DEADLINE - MAY 2, 2016 (5:00 PM)**

The Indiana Clinical and Translational Sciences Institute (CTSI) in conjunction with the Division of Gastroenterology/Hepatology in the Department of Medicine is soliciting proposals for pilot projects from investigators to develop and promote translational and transdisciplinary collaborative research projects in adult gastrointestinal and liver diseases. The objective is to fund studies that (a) establish or strengthen already established collaborations between faculty members in the GI Division and investigators from other departments and schools at IUSM, IUPUI and Purdue University; (b) generate preliminary data for extramural funding applications investigating adult GI and liver disorders.

The areas of interest include (a) acute and chronic liver diseases; (b) GI and hepatobiliary malignancy; (c) inflammatory bowel disease; (d) GI motility disorders; (e) chronic abdominal pain; and (f) chronic functional bowel disorders. The proposal should demonstrate tangible evidence that the collaboration will lead to a multiyear federal grant application.

Applications to this program are **limited to \$35,000** and are of **one (1) year duration**. Up to two grants will be awarded per grant cycle.

Pilot Funding For Research Use of Core Facilities - 2016.05

**SUBMISSION DEADLINE - MAY 16, 2016.** The Indiana CTSI Pilot Funding program is intended to promote the use of technologies and expertise afforded by the Indiana CTSI Core Facilities available at all partner institutions. Successful proposals will demonstrate outstanding scientific merit that can be linked to generating extramural funding or novel intellectual property (IP). Success of the program will be viewed, in part, by the fostering of new funded grants or providing significant contributions to grant renewals. Therefore, proposals will be judged with equal measure on scientific merit and the likelihood of generating new IP or extramural grant support.

Indiana CTSI/IUSM Core Equipment Funding - 2016.03

**SUBMISSION DEADLINE EXTENDED - Original Date MARCH 25 has been extended to APRIL 22, 2016 (5:00 PM).** The Indiana CTSI is seeking proposals from CTSI-Designated, IUSM-based Cores requesting support for the purchase of equipment that will enhance the research environment and contribute to the research mission of the School and the CTSI. Up to \$100,000 will be available through this solicitation. Proposals requesting \$5,000-\$100,000 will be accepted. Requests for equipment costing more than \$100,000 will be entertained if matching funds to cover the balance are identified.

Collaboration in Translational Research Pilot Grant Program - 2016.03

**SUBMISSION DEADLINE - MARCH 4, 2016 (5:00 PM).** The Indiana Clinical and Translational Science Institute (CTSI) is seeking applicants for the Collaboration in Translational Research (CTR) Pilot Grant Program. The objective of the Indiana CTSI CTR pilot grant program is to foster and encourage collaboration across the Indiana CTSI partner institutions (IU, Purdue, and Notre Dame) and to initiate or continue translational research projects that have very strong and immediate potential to develop into larger, externally funded research programs, or generate novel intellectual property (IP). Proposed projects should have participation by two (or more) principal investigators representing at least two of the sponsoring affiliates for this program. Sponsoring affiliates include: Indiana University School of Medicine (IUSM), IUPUI (non-IUSM), Indiana University-Bloomington, Purdue University-West Lafayette, and University of Notre Dame.

CTSI Postdoctoral Training Awards in Translational Research - 2016.02

**SUBMISSION DEADLINE - FEBRUARY 1, 2016 (5:00 PM).** The Indiana Clinical and Translational Sciences Institute (CTSI) is seeking applicants for special postdoctoral training awards in translational research. In biomedical terminology, translational research refers to what is popularly termed as "bench to bedside"; the process by which research in the lab translates into patient treatment. Translation may involve applying discoveries made during research (in the lab, through animal studies, etc.) to the development of clinical trials and studies in humans, or carrying out research aimed at enhancing the adoption of best practices, or both. To be eligible, candidates must have received a PhD or equivalent degree from an accredited domestic or foreign institution. Please refer to the competition guidelines for full eligibility criteria.

CTSI Postdoc Challenge: Grand Funding to use CTSI-Designated Core Facilities - 2016.02

**SUBMISSION DEADLINE - FEBRUARY 29, 2016 (5:00 PM).** The Indiana Clinical and Translational Sciences Institute (CTSI) is seeking applicants for special postdoctoral training awards in translational research. In biomedical terminology, translational research refers to what is popularly termed as "bench to bedside"; the process by which research in the lab translates into patient treatment. Translation involve applying discoveries made during research (in the lab, through animal studies, etc.) to the development of clinical trials and studies in humans, or carrying out research aimed at enhancing the adoption of best practices.

CTSI-Designated Core Facilities are cores that undergo a yearly accreditation process through the Indiana CTSI for all partner institutions. The Postdoc Challenge offers postdoctoral research associates at Indiana University, Purdue University, and the University of Notre Dame valuable proposal writing and reviewing experience in areas related to translational research through the use of one or more of the CTSI-Designated Core Facilities at these universities. This is a competitive opportunity for two 1-year awards of \$5000 each per institution in the form of an expense account for use of core facility services. Funding is to be used only for services provided by the core facilities. Indiana CTSI-Designated Core Facilities are listed on the HUB (<https://www.indianactsi.org/servicecores>). If you are interested in participating, you must discuss your proposal with your advisor prior to beginning the application process to ensure your participation will be approved.

Support & Feedback

Citing CTSI

Newsletter

Grants Login

This website is supported by [Indiana](#) and [Purdue](#) universities. Design by [JUPUI](#); concept by [Tufts CTSI](#).  
Copyright © 2014 Indiana CTSI

Contact:  
[info@indianactsi.org](mailto:info@indianactsi.org)

Symposium, Workshop, and Conference Funding Program RFA

**SUBMISSION DEADLINE - OPEN.** The Indiana CTSI symposium, conference and workshop funding program is intended to facilitate sharing of ideas and findings in face-to-face discussion environments. The proposed symposium should include a translational research focus. The Indiana CTSI symposium program is specifically established to support presentation of new information to researchers in the Indiana CTSI that will establish research connections and lead to new research communication forums and ongoing collaborations. The application should describe how the proposed symposium will meet these goals.

[START](#)

